Industries > Pharma > Needle-Free Delivery Technology Market 2018-2028

Needle-Free Delivery Technology Market 2018-2028

Jet Injector Technology, Competing Technologies, Novel Needle Technology, Inhaler Technology, Patch Technology

PUBLISHED: 21 August 2018
PAGES: 183
PRODUCT CODE: PHA0327
SUBMARKET: Medical Devices

Clear
WOOCS 2.2.1
SKU: PHA0327 Categories: , Tags: , , , , , ,

The global needle-free delivery technology market was valued at $1.7bn in 2017 and is estimated to reach $5.5bn by 2028, growing at a CAGR of 11.5% from 2018-2028. In 2017, the Jet Injectors submarket held 45.1% of the global needle-free delivery technology market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 183-page report you will receive 107 charts– all unavailable elsewhere.

The 183-page report provides clear detailed insight into the global needle-free delivery technology market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Needle-Free Delivery Technology market forecasts from 2018-2028

Jet Injector submarket forecasts from 2018-2028

Competing Technology submarket forecast from 2018-2028, further segmented into:
• Novel Needle Technology
• Inhaler Technology
• Patch Technology

• This report also breaks down the revenue forecast for global needle-free delivery technology market by regional and national market:
• The US
• EU5: Germany, France, UK, Italy, Spain
• Japan
• China
• India

Needle-Free Delivery Technology Market 2018-2028

• This report discusses the leading companies that are involved in the needle-free delivery technology market. It contains overviews of the companies’ activities, strategies and recent financial results:
• 3M
• Antares Pharma
• Becton Dickinson
• BioJect Medical Technologies
• PharmaJet
• Zogenix

• This report provides a SWOT Analysis of the global needle-free delivery technology market.

Visiongain’s study is for everybody needing commercial analyses for the needle-free delivery technology market and leading companies. You will find data, trends and predictions. Please order our report now.

Buy our report today Needle-Free Delivery Technology Market Forecast 2018-2028: Jet Injector Technology, Competing Technologies, Novel Needle Technology, Inhaler Technology, Patch Technology.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Needle-Free Delivery Technology Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Needle-Free Delivery Technology Market 2018-2028


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category